Form 4: Enliven COO Sells Shares Under 10b5-1 Plan

Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold 6,667 shares of common stock through a pre-arranged trading plan.

Summary

• Anish Patel, Chief Operating Officer of Enliven Therapeutics, Inc. (ELVN), reported sales of common stock.
• The transactions occurred on August 7, 2025.
• A total of 6,262 shares were sold at a weighted average price of $18.1969 per share.
• An additional 405 shares were sold at a weighted average price of $18.9297 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024.
• The shares were held indirectly by The Patel / Dong Family Trust, for which Anish Patel serves as trustee.
• Following these transactions, the indirect beneficial ownership stands at 289,975 shares.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction filing under a pre-arranged 10b5-1 plan, which typically does not carry significant positive or negative sentiment regarding the company's operational performance or outlook.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider stock transactions.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024, by the Reporting Person and by The Patel / Dong Family Trust.
• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate sale price upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sectors. Insider sales under a 10b5-1 plan are pre-scheduled and often not indicative of management's immediate view on company prospects.

Comparison to Industry Standards

• This filing is a standard insider transaction report and does not contain information that allows for a direct comparison to industry-specific operational or financial benchmarks.
• Insider trading activity, particularly under a 10b5-1 plan, is a common practice across all industries for liquidity or diversification purposes and does not inherently reflect company performance relative to peers like Moderna, Pfizer, or other biotech firms.

Related Party Transactions

• The shares sold were held by The Patel / Dong Family Trust, for which the Reporting Person, Anish Patel, serves as trustee. This constitutes a related party transaction as the trust is controlled by the reporting insider.

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Operating Officer, even under a pre-arranged plan, could be perceived by some shareholders as a lack of confidence, though 10b5-1 plans are often for personal financial planning. The total shares sold represent a small fraction of the company's outstanding shares and the insider's total holdings.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate sale price upon request by the SEC staff, the Issuer, or a security holder.

Key Dates

Recommendation

This Form 4 filing reports a routine insider sale executed under a pre-arranged 10b5-1 trading plan. Such sales are typically for personal financial planning, diversification, or liquidity and are not usually indicative of a change in the company's fundamental outlook or performance. Therefore, this specific filing alone does not provide sufficient new information to warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Enliven Therapeutics, ELVN, Anish Patel, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Officer Transaction, Biotechnology, Pharmaceuticals